Kim Chi is a medical oncologist and the Chief Medical Officer of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia (BC), in Canada. He is also Professor of Medicine at the University of British Columbia, in Vancouver, BC. Prof. Chi studied medicine and completed a residency in internal medicine at the University of Ottawa, ON, Canada, before undertaking a fellowship in medical oncology at the University of British Columbia.
Prof. Chi's research in the field of genitourinary cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer. Recently, he has been investigating circulating tumour DNA as a potential prognostic and predictive biomarker for patients with castration-resistant prostate cancer. Prof. Chi is a former Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group, and has held peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defence, Movember, Prostate Cancer Foundation (USA), and Prostate Cancer Canada.
Prof. Chi has
published widely in prestigious peer-reviewed journals including most recently
the Journal of Clinical Oncology, Annals of Oncology, the New
England Journal of Medicine, and Lancet Oncology.